Flashwater HAS patented product Pioneering internationally leading targeted anti-biofilm therapy Terminator of oral health problems.

The World Health Organization (WHO) 2024 Bangkok Declaration has designated oral health as a global public health priority, highlighting that oral diseases affect nearly half of the world’s population (3.5 billion people) and are the most common noncommunicable diseases. Notably, the majority of oral health issues are preventable and amenable to effective treatment through early intervention.

In November 2024, experts from the top 30 dental hospitals in China released a consensus, identifying three critical limitations of oral clinical irrigants and care products: poor biocompatibility, impairment of wound healing, and high corrosiveness. To date, no single irrigant has been able to meet all clinical requirements safely and without adverse effects.

The 2025 Expert Consensus on the Management of Peri-implant Diseases indicates that the prevalence of peri-implant mucositis reaches 43%, with plaque biofilm identified as the core risk factor. Plaque control is not only the key to treatment but also an effective measure for the prevention of peri-implantitis.

In September 2025, a study jointly conducted by Flashwater, the Chairman of the Periodontology Committee of the Chinese Stomatological Association, the National Key Laboratory of Stomatology, and Jiangsu Stomatological Hospital was published in an authoritative international journal. This study confirmed that Flashwater’s proprietary HAS factor possesses ten key advantages, with its core mechanism being a “information warfare” approach targeting bacterial quorum sensing. Instead of relying on high concentrations to kill bacteria, it disrupts bacterial communication at low doses, effectively inhibiting biofilm and plaque formation while maintaining microbial flora balance and promoting wound healing.

In February 2026, the Chinese Center for Disease Control and Prevention (China CDC) clarified that biofilm is the primary pathogenic agent responsible for most oral diseases, including halitosis, periodontal disease, and gingivitis.

Relevant academic literature verifies that Flashwater’s proprietary HAS factor has pioneered a world-leading novel anti-biofilm technology for oral health problems, opening new possibilities for the supportive care of periodontitis and related conditions.

Flashwater’s HAS factor offers comprehensive support for the oral mucosal environment, aligning with the daily adjunctive management of periodontal concerns, while demonstrating outstanding potential as an auxiliary option for root canal irrigation. It fully accommodates the multifaceted demands of oral care management.

The new Flashwater Mouthwash has obtained FDA registration and SGS report. With high cost-effectiveness, it can help reduce reliance on in-clinic professional oral care routine. Additionally, it can be diluted up to 14 times, enabling flexible use and reducing overall costs.